|
000
| 01958nam 2200385zi 4500 |
|---|
| 001 | 9.880801 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20221107165854 |
|---|
| 006 | m o d f |
|---|
| 007 | cr cn||||||||| |
|---|
| 008 | 191018t20192020onca ob f000 0 eng d |
|---|
| 020 | |a9780660329550 |
|---|
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aH164-281/1-2019E-PDF |
|---|
| 245 | 00|aGuidance document : |bpost-notice of compliance (NOC) changes : safety and efficacy document (for pharmaceutical, biologic and radiopharmaceutical drugs for human use only). |
|---|
| 246 | 17|aPost-notice of compliance (NOC) changes : |bsafety and efficacy document (for pharmaceutical, biologic and radiopharmaceutical drugs for human use only) |
|---|
| 264 | 1|aOttawa, ON : |bHealth Canada = Santé Canada, |c2019. |
|---|
| 264 | 4|c©2020 |
|---|
| 300 | |a1 online resource (24 pages) |
|---|
| 336 | |atext|btxt|2rdacontent |
|---|
| 337 | |acomputer|bc|2rdamedia |
|---|
| 338 | |aonline resource|bcr|2rdacarrier |
|---|
| 500 | |aIssued also in French under title: Ligne directrice : changements survenus après l'avis de conformité (AC) : document sur l'innocuité et l'efficacité (pour les produits biologiques, pharmaceutiques et radiopharmaceutiques à usage humain seulement). |
|---|
| 500 | |a"Publication date: November 2019." |
|---|
| 500 | |a"Pub.: 190400." |
|---|
| 500 | |aIssued also in HTML format. |
|---|
| 504 | |6Includes bibliographical references. |
|---|
| 650 | 0|aDrugs|xLabeling|zCanada. |
|---|
| 650 | 0|aDrug approval|zCanada. |
|---|
| 710 | 1 |aCanada. |bHealth Canada, |eissuing body. |
|---|
| 775 | 08|tLigne directrice : |w(CaOODSP)9.880804 |
|---|
| 856 | 40|qPDF|s345 KB|uhttps://publications.gc.ca/collections/collection_2020/sc-hc/H164-281-1-2019-eng.pdf |
|---|
| 856 | 4 |qHTML|sN/A|uhttps://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/post-notice-compliance-changes/safety-efficacy-2019/document.html |
|---|